CVS Health shares moved lower Wednesday after its insurance subsidiary Aetna agreed to pay $117.7 million to resolve U.S. government allegations that it submitted inaccurate diagnosis codes for Medicare Advantage enrollees. CVS stock fell to $75.68, down 0.85% today, as investors reacted to the legal settlement involving one of the company’s largest business segments.
The civil settlement, announced by the U.S. Department of Justice, resolves claims that Aetna violated the federal False Claims Act by submitting diagnosis data that allegedly overstated certain health conditions in order to receive higher government payments.
CVS Health said the company agreed to resolve the matter to avoid the uncertainty and expense associated with prolonged litigation and emphasized that the settlement does not represent an admission of wrongdoing.
Details of the Aetna Medicare fraud allegations
According to federal prosecutors, the allegations focused on how Aetna reported diagnosis codes tied to morbid obesity and other health conditions among Medicare Advantage members. The Justice Department said that between 2018 and 2023 the insurer submitted diagnosis data that was inconsistent with patient records, particularly involving reported body mass index measurements.
Morbid obesity diagnoses can significantly affect how insurers are reimbursed under Medicare Advantage because the program adjusts payments based on a patient’s health risk profile. Insurers receive higher payments for patients who are considered sicker or who have more complex health conditions.
Authorities also alleged that Aetna failed to withdraw inaccurate diagnosis codes that it identified during a review of patients’ medical records tied to earlier coding activity from 2015.
The settlement resolves a lawsuit filed in January 2024 in federal court in Philadelphia by Mary Melette Thomas, an Arizona resident and former Aetna risk adjustment coding auditor who alleged the company knowingly submitted inaccurate diagnosis data.
Under the False Claims Act, whistleblowers who report fraud involving government programs can receive a portion of any recovery. In this case, Thomas will receive approximately $2.01 million from the settlement.
The Justice Department detailed the enforcement action in its official announcement regarding the case involving Medicare Advantage billing practices. Readers can review the full case information in the Department of Justice settlement release.
How Medicare Advantage payments work
Medicare Advantage, also known as Medicare Part C, allows private insurers to offer healthcare coverage to seniors who choose an alternative to traditional Medicare. Under the program, insurers known as Medicare Advantage Organizations receive payments from the government to manage care for enrolled beneficiaries.
The amount insurers receive is partly determined through a system called risk adjustment. Under this model, insurers receive higher payments when patients are diagnosed with conditions that indicate higher expected healthcare costs.
The Centers for Medicare & Medicaid Services collects diagnosis codes from insurers to calculate these payments. If certain conditions are reported, the insurer’s reimbursement level increases accordingly.
This structure has made diagnosis coding an important compliance area for insurers participating in Medicare Advantage programs. More information about how the system operates can be found through the CMS risk adjustment overview.
Medicare Advantage under growing scrutiny
The settlement also underscores the increasing scrutiny surrounding Medicare Advantage billing practices. Private insurers collectively receive more than $530 billion each year from the federal government to manage healthcare for Medicare Advantage beneficiaries, according to federal officials.
As spending on the program has expanded rapidly, regulators have intensified oversight of diagnosis coding and payment calculations to ensure insurers are not receiving inflated reimbursements.
Assistant Attorney General Brett Shumate said in a statement that accurate diagnosis data is critical to ensuring the integrity of government healthcare programs and protecting taxpayer funds.
In recent years, federal investigators have pursued several enforcement actions involving alleged Medicare Advantage overpayments, making compliance and coding practices a growing focus for the healthcare insurance industry.
CVS response to the settlement
CVS Health said it disagrees with the government’s broader allegations about industry billing practices and reiterated that the company resolved the matter to avoid lengthy litigation.
“Aetna continues to disagree with the DOJ’s industry-wide allegations, and this settlement should not be seen as an acknowledgment of liability,” CVS said in its statement following the announcement.
CVS acquired Aetna in 2018 as part of a $69 billion deal that transformed the pharmacy giant into a vertically integrated healthcare company combining insurance, pharmacy benefits, retail clinics, and pharmacy operations.
Market reaction to the news
Despite the legal headline, the stock’s reaction was relatively modest. CVS shares slipped about 0.85% to $75.68 following the announcement, suggesting investors view the settlement as a contained financial event rather than a major operational setback.
The $117.7 million payment is small compared with CVS Health’s overall financial scale. The company generates hundreds of billions of dollars in annual revenue, meaning the settlement represents only a minor portion of its financial resources.
However, the case still highlights the regulatory risks facing large healthcare insurers that participate heavily in government-backed programs.
What investors will watch next
For investors, the key issue may not be the settlement amount itself but the broader regulatory environment around Medicare Advantage. The program remains a critical growth engine for many large insurers, including CVS, UnitedHealth Group, and Humana.
If regulators increase enforcement efforts or tighten reimbursement rules, the industry could face additional compliance costs or changes to how risk adjustment payments are calculated.
For now, CVS investors appear to be treating the settlement as a manageable legal resolution. Still, the case serves as a reminder that healthcare companies operating within government-funded programs remain subject to close scrutiny from regulators and federal investigators.
Make Swikblog your go-to source on Google for reliable updates, smart insights, and daily trends.
